Shamburg News · 8-K filed Nov 12, 2026, 4:25 PM EST
Nektar Therapeutics Reports Third Quarter 2026 Results and Advances Rezpegaldesleukin Phase 3
NKTR · NEKTAR THERAPEUTICS
- Earnings
- Financial statements
- Materiality: high
Nektar Therapeutics reported a third quarter 2026 net loss of $55.7 million, or $1.63 per basic and diluted share, compared with a net loss of $35.5 million, or $1.87 per share, in the third quarter of 2025. Third quarter 2026 revenue was $9.4 million versus $11.8 million a year earlier, and total operating costs and expenses rose to $67.2 million from $43.5 million. Cash and investments in marketable securities were $952.9 million at September 30, 2026, and the company reported initiation of the ZENITH AD-3 Phase 3 trial in atopic dermatitis.
Source: SEC EDGAR, Form 8-K, Items 2.02, 9.01, accession 0001213900-26-118964.
Written from the filing by Shamburg Markets. Figures are as reported by the company.